Simultaneous determination of human plasma levels of four selective serotonin reuptake inhibitors by high-performance liquid chromatography.
A reversed-phase high-performance liquid chromatography (HPLC) method with fluorimetric detection, which allows the simultaneous determination of plasma concentrations of four selective serotonin reuptake inhibitors (SSRIs) is presented. Fluvoxamine, paroxetine, sertraline, and fluoxetine were extracted from plasma with ethyl acetate and then derivatized with dansyl chloride. The analytes were separated using Hypersyl ODS C18 (5 microm) 250 x 4.6 mm column (ThermoQuest, Runcorn, UK). For continuous gradient separation, the mobile phase consists of two eluents, acetonitrile and potassium phosphate buffer (10 mmol/L, pH 7.2) at total flow rate of 1.5 mL/min. Detection was carried out at lambda exc = 366 nm and lambda em = 490 nm. The authors found recoveries of 90% to 95% for fluvoxamine, 94% to 100% for paroxetine, 88% to 95% for sertraline, 93% to 100% for fluoxetine, and 97% to 100% for internal standard (nortriptyline). Imprecision of the method ranged from 2.5% to 8.9%. The assay was linear from 10 to 1500 ng/mL for sertraline, and from 5 to 1500 ng/mL for the other drugs. The authors conclude that this method is suitable for monitoring antidepressant therapy. In addition, the authors report the effects of adding paroxetine to fluvoxamine on plasma levels in a group of patients in combined drug therapy.
Lucca
A
A
Istituto Scientifico Ospedale San Raffaele, Department of Neuropsychiatric Sciences, Milan, Italy.
Gentilini
G
G
Lopez-Silva
S
S
Soldarini
A
A
D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000097:blood* / Q000302:isolation & purification / Q000494:pharmacology; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D003865:Major Depressive Disorder / Q000097:blood / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D005470:Fluorometry / Q000379:methods; D005473:Fluoxetine / Q000097:blood / Q000302:isolation & purification; D016666:Fluvoxamine / Q000097:blood / Q000302:isolation & purification / Q000494:pharmacology; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D017374:Paroxetine / Q000097:blood / Q000302:isolation & purification / Q000494:pharmacology; D012680:Sensitivity and Specificity; D017367:Selective Serotonin Reuptake Inhibitors / Q000097:blood* / Q000302:isolation & purification / Q000494:pharmacology; D020280:Sertraline / Q000097:blood / Q000302:isolation & purification
D018687:Antidepressive Agents, Second-Generation; D005473:Fluoxetine; D016666:Fluvoxamine; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline